Cannvas MedTech (CSE:MTEC) CEO Shawn Moniz has developed his company’s business model around serving the educational needs of cannabis consumers.

In the interview below, Moniz discusses Cannvas MedTech’s approach to making cannabis-based information for medicinal, adult and even petcare use readily available to consumers across its online platforms. He also addresses the company’s role in developing data analytics services for the cannabis industry.

Below is the video of our interview with Cannvas MedTech CEO Shawn Moniz. It is followed by a transcript that has been edited for clarity and brevity.

Investing News Network: Please give our investor audience an overview of Cannvas MedTech and its technology platforms for the cannabis industry.

Cannvas MedTech CEO Shawn Moniz: At Cannvas MedTech we are a business technology company and we have developed a number of patient-centric data platforms. These platforms are curated to put the patient first within the healthcare space. Patients can use our interactive tools to learn about the different uses of cannabis, talk to a physician, read articles and explore our educational content.

Beneath the surface, we are pioneers in data analytics for the cannabis space. We use our analytics to try to determine a user’s next interaction based upon their previous one. To do this, we use our insight into the categories being learned about, the click-throughs on CRM emails, and more to determine user behaviour traits. These behaviour traits then guide our content curation, ensuring constant engagement throughout the platform.

INN: What is the current landscape of consumer knowledge in the cannabis industry at the moment? How is Cannvas looking to mitigate the existing gap?

SM: It’s a pretty wide gap. There are people that are just entering the cannabis space, and people that have been in the industry for 20, 30 and 40 years, and for all users, education is prime. Everyone still needs to learn more about what it means to go on different strains, the various methods of ingestion, when they should talk to their doctor and what about, whether they can travel with cannabis, and more. Patients want to know how to effectively incorporate cannabis into their healthcare and on the platform, education for the patient comes first.

INN: How does data and analytics play a role in the cannabis industry? How is Cannvas implementing these tools?

SM: One of the biggest opportunities for Cannvas MedTech lies in the cannabis data space. We use our tools to learn about behaviour traits, what the industry is doing and what it isn’t, the different likes, needs and wants of patients, and the adult use market. By honing in on what the key elements of the market are, we can channel that information back to the community through insightful reports. We are working with different academic communities, physicians and Health Canada to develop a picture on what the cannabis landscape looks like with the data to back it up. We feel that this is a crucial gap that Cannvas MedTech can help address.

INN: Cannvas recently announced its Cannvas.PET platform. How is cannabis extending its reach into the petcare industry?

SM: Cannabis has already reached into the petcare space with people giving CBD oil and hemp-infused products to their pets. Similarly to the adult-use market, however, people started using these products before being fully educated. We want to provide this community with education that is segmented whether you have a bird, a lizard, a cat or a dog, and then further categorized depending on the weight and age of your pet. We also want to inform pet owners on the conversations they need to have with their vets if they want to use cannabis as part of their pet’s healthcare routine. For all this we are launching an educational platform for your furry friend.

INN: What is next for Cannvas MedTech and how does that fit into the company’s long-term plans?

SM: Our long-term plan is to be the household name of cannabis education, and there are a few ways in which we are doing that. We are vertically integrating our company through our white label solutions under Cannvas Health, getting into pharmacies, clinics and healthcare communities. We are also trying to get into palliative care units within hospitals, extending our education contributions within the different elements of the industry globally, not just within Canada.

We are getting our name out there by entering the brick-and-mortar space while also tackling the digital environments in these clinics and healthcare communities. What we see on the horizon is more global expansion for Cannvas MedTech.

CEO interviews are part of investor education campaigns for clients advertising on the Investing News Network. Important news is contextualized by CEOs, and the resulting interviews are disseminated to the Investing News Network audience because they have value to market watchers.

The Investing News Network interviews a CEO for an understanding of their perspective on the company, the investment potential of the company and market news related to the company. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. 

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less